{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T08:29:16Z","timestamp":1790152156807,"version":"4.0.1"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,11,4]],"date-time":"2016-11-04T00:00:00Z","timestamp":1478217600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2016,11,4]],"date-time":"2016-11-04T00:00:00Z","timestamp":1478217600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Immunogenicity of recombinant human acid-alpha glucosidase (rhGAA) in enzyme replacement therapy (ERT) is a safety and efficacy concern in the management of late-onset Pompe disease (LOPD). However, long-term effects of ERT on humoral and cellular responses to rhGAA are still poorly understood. To better understand the impact of immunogenicity of rhGAA on the efficacy of ERT, clinical data and blood samples from LOPD patients undergoing ERT for &gt;4 years (n\u2009=\u200928) or untreated (n\u2009=\u200910) were collected and analyzed. In treated LOPD patients, anti-rhGAA antibodies peaked within the first 1000 days of ERT, while long-term exposure to rhGAA resulted in clearance of antibodies with residual production of non-neutralizing IgG. Analysis of\u2009 T cell responses to rhGAA showed detectable T cell reactivity only after <jats:italic>in vitro<\/jats:italic> restimulation. Upregulation of several cytokines and chemokines was detectable in both treated and untreated LOPD subjects, while IL2 secretion was detectable only in subjects who received ERT. These results indicate that long-term ERT in LOPD patients results in a decrease in antibody titers and residual production of non-inhibitory IgGs. Immune responses to GAA following long-term ERT do not seem to affect efficacy of ERT and are consistent with an immunomodulatory effect possibly mediated by regulatory T cells.<\/jats:p>","DOI":"10.1038\/srep36182","type":"journal-article","created":{"date-parts":[[2016,11,4]],"date-time":"2016-11-04T12:39:54Z","timestamp":1478263194000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Long-term exposure to Myozyme results in a decrease of anti-drug antibodies in late-onset Pompe disease patients"],"prefix":"10.1038","volume":"6","author":[{"given":"Elisa","family":"Masat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Lafor\u00eat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"De Antonio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Corre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Perniconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadjib","family":"Taouagh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuberaka","family":"Mariampillai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damien","family":"Amelin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wladimir","family":"Mauhin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Yves","family":"Hogrel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Caillaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Ronzitti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Puzzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaudia","family":"Kuranda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasqualina","family":"Colella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Mallone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Benveniste","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Mingozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"French Pompe Registry Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Bassez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. L.","family":"Bedat-Millet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Behin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Eymard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Leonard-Louis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Stojkovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Canal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Decostre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Bouhour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Boyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Castaing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Chapon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Cintas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Durieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Echaniz-Laguna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Feasson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Furby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Hamroun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Ferrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Sol\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Froissart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Piraud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Germain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Benistan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Guffon-Fouilhoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Journel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Labauge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Lacour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Magot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"P\u00e9r\u00e9on","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. -C.","family":"Minot-Myhi\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Nadaj-Pakleza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Nathier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Orlikowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Pellegrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Petiot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Praline","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Lofaso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Prigent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Dutry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Renard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Sacconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Desnuelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Salort-Campana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Pouget","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Tiffreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Vincent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Zagnoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,11,4]]},"reference":[{"key":"BFsrep36182_CR1","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1016\/S0140-6736(08)61555-X","volume":"372","author":"AT van der Ploeg","year":"2008","unstructured":"van der Ploeg, A. T. & Reuser, A. J. Pompe\u2019s disease. Lancet 372, 1342\u20131353, doi: 10.1016\/S0140-6736(08)61555-X (2008).","journal-title":"Lancet"},{"key":"BFsrep36182_CR2","unstructured":"Hirschhorn, R. a. R. AJJ. In The Metabolic and Molecular Basis of Inherited Disease (ed A. L. Beaudet, C. R. Scriver, W. S. Sly, D. Valle ) 3389\u20133420 (McGraw-Hill, 2001)."},{"key":"BFsrep36182_CR3","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1002\/ajmg.c.31318","volume":"160C","author":"M Kroos","year":"2012","unstructured":"Kroos, M., Hoogeveen-Westerveld, M., van der Ploeg, A. & Reuser, A. J. The genotype-phenotype correlation in Pompe disease. Am J Med Genet C Semin Med Genet 160C, 59\u201368, doi: 10.1002\/ajmg.c.31318 (2012).","journal-title":"Am J Med Genet C Semin Med Genet"},{"key":"BFsrep36182_CR4","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.ymgme.2009.08.003","volume":"99","author":"PS Kishnani","year":"2010","unstructured":"Kishnani, P. S. et al. Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants. Mol Genet Metab 99, 26\u201333, doi: 10.1016\/j.ymgme.2009.08.003 (2010).","journal-title":"Mol Genet Metab"},{"key":"BFsrep36182_CR5","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.nmd.2011.04.001","volume":"21","author":"D Orlikowski","year":"2011","unstructured":"Orlikowski, D. et al. Recombinant human acid alpha-glucosidase (rhGAA) in adult patients with severe respiratory failure due to Pompe disease. Neuromuscul Disord 21, 477\u2013482, doi: 10.1016\/j.nmd.2011.04.001 (2011).","journal-title":"Neuromuscul Disord"},{"key":"BFsrep36182_CR6","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1055\/s-0033-1334469","volume":"32","author":"JW Teener","year":"2012","unstructured":"Teener, J. W. Late-onset Pompe\u2019s disease. Semin Neurol 32, 506\u2013511, doi: 10.1055\/s-0033-1334469 (2012).","journal-title":"Semin Neurol"},{"key":"BFsrep36182_CR7","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1212\/01.wnl.0000251268.41188.04","volume":"68","author":"PS Kishnani","year":"2007","unstructured":"Kishnani, P. S. et al. Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology 68, 99\u2013109, doi: 10.1212\/01.wnl.0000251268.41188.04 (2007).","journal-title":"Neurology"},{"key":"BFsrep36182_CR8","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1038\/gim.2012.44","volume":"14","author":"SN Prater","year":"2012","unstructured":"Prater, S. N. et al. The emerging phenotype of long-term survivors with infantile Pompe disease. Genet Med 14, 800\u2013810, doi: 10.1038\/gim.2012.44 (2012).","journal-title":"Genet Med"},{"key":"BFsrep36182_CR9","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.ymgme.2012.09.015","volume":"107","author":"AT van der Ploeg","year":"2012","unstructured":"van der Ploeg, A. T. et al. Open-label extension study following the Late-Onset Treatment Study (LOTS) of alglucosidase alfa. Mol Genet Metab 107, 456\u2013461, doi: 10.1016\/j.ymgme.2012.09.015 (2012).","journal-title":"Mol Genet Metab"},{"key":"BFsrep36182_CR10","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1056\/NEJMoa0909859","volume":"362","author":"AT van der Ploeg","year":"2010","unstructured":"van der Ploeg, A. T. et al. A randomized study of alglucosidase alfa in late-onset Pompe\u2019s disease. N Engl J Med 362, 1396\u20131406, doi: 10.1056\/NEJMoa0909859 (2010).","journal-title":"N Engl J Med"},{"key":"BFsrep36182_CR11","doi-asserted-by":"crossref","unstructured":"Schoser, B. et al. Survival and long-term outcomes in late-onset Pompe disease following alglucosidase alfa treatment: a systematic review and meta-analysis. J Neurol, doi: 10.1007\/s00415-016-8219-8 (2016).","DOI":"10.1007\/s00415-016-8219-8"},{"key":"BFsrep36182_CR12","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1056\/NEJMc0806809","volume":"360","author":"NJ Mendelsohn","year":"2009","unstructured":"Mendelsohn, N. J., Messinger, Y. H., Rosenberg, A. S. & Kishnani, P. S. Elimination of antibodies to recombinant enzyme in Pompe\u2019s disease. N Engl J Med 360, 194\u2013195, doi: 10.1056\/NEJMc0806809 (2009).","journal-title":"N Engl J Med"},{"key":"BFsrep36182_CR13","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.ymgme.2012.01.019","volume":"105","author":"SG Banugaria","year":"2012","unstructured":"Banugaria, S. G. et al. Persistence of high sustained antibodies to enzyme replacement therapy despite extensive immunomodulatory therapy in an infant with Pompe disease: need for agents to target antibody-secreting plasma cells. Mol Genet Metab 105, 677\u2013680, doi: 10.1016\/j.ymgme.2012.01.019 (2012).","journal-title":"Mol Genet Metab"},{"key":"BFsrep36182_CR14","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1097\/GIM.0b013e31819d0996","volume":"11","author":"M Nicolino","year":"2009","unstructured":"Nicolino, M. et al. Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease. Genet Med 11, 210\u2013219, doi: 10.1097\/GIM.0b013e31819d0996 (2009).","journal-title":"Genet Med"},{"key":"BFsrep36182_CR15","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.ymgme.2010.08.009","volume":"101","author":"JM de Vries","year":"2010","unstructured":"de Vries, J. M. et al. High antibody titer in an adult with Pompe disease affects treatment with alglucosidase alfa. Mol Genet Metab 101, 338\u2013345, doi: 10.1016\/j.ymgme.2010.08.009 (2010).","journal-title":"Mol Genet Metab"},{"key":"BFsrep36182_CR16","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.ymgme.2011.07.004","volume":"104","author":"AH El-Gharbawy","year":"2011","unstructured":"El-Gharbawy, A. H. et al. An individually, modified approach to desensitize infants and young children with Pompe disease, and significant reactions to alglucosidase alfa infusions. Mol Genet Metab 104, 118\u2013122, doi: 10.1016\/j.ymgme.2011.07.004 (2011).","journal-title":"Mol Genet Metab"},{"key":"BFsrep36182_CR17","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1111\/j.1523-1755.2004.00924.x","volume":"66","author":"GE Linthorst","year":"2004","unstructured":"Linthorst, G. E., Hollak, C. E., Donker-Koopman, W. E., Strijland, A. & Aerts, J. M. Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta. Kidney Int 66, 1589\u20131595, doi: 10.1111\/j.1523-1755.2004.00924.x (2004).","journal-title":"Kidney Int"},{"key":"BFsrep36182_CR18","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/S0027-5107(01)00232-9","volume":"483","author":"DP Germain","year":"2001","unstructured":"Germain, D. P., Kaneski, C. R. & Brady, R. O. Mutation analysis of the acid beta-glucosidase gene in a patient with type 3 Gaucher disease and neutralizing antibody to alglucerase. Mutat Res 483, 89\u201394 (2001).","journal-title":"Mutat Res"},{"key":"BFsrep36182_CR19","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1002\/mus.22136","volume":"44","author":"M Banati","year":"2011","unstructured":"Banati, M., Hosszu, Z., Trauninger, A., Szereday, L. & Illes, Z. Enzyme replacement therapy induces T-cell responses in late-onset Pompe disease. Muscle Nerve 44, 720\u2013726, doi: 10.1002\/mus.22136 (2011).","journal-title":"Muscle Nerve"},{"key":"BFsrep36182_CR20","doi-asserted-by":"publisher","first-page":"e98336","DOI":"10.1371\/journal.pone.0098336","volume":"9","author":"S Nayak","year":"2014","unstructured":"Nayak, S. et al. Immune responses and hypercoagulation in ERT for Pompe disease are mutation and rhGAA dose dependent. PLoS One 9, e98336, doi: 10.1371\/journal.pone.0098336 (2014).","journal-title":"PLoS One"},{"key":"BFsrep36182_CR21","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.ymgme.2012.03.009","volume":"106","author":"S Nayak","year":"2012","unstructured":"Nayak, S. et al. Mapping the T helper cell response to acid alpha-glucosidase in Pompe mice. Mol Genet Metab 106, 189\u2013195, doi: 10.1016\/j.ymgme.2012.03.009 (2012).","journal-title":"Mol Genet Metab"},{"key":"BFsrep36182_CR22","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/mt.2009.195","volume":"18","author":"B Sun","year":"2010","unstructured":"Sun, B. et al. Immunomodulatory gene therapy prevents antibody formation and lethal hypersensitivity reactions in murine pompe disease. Mol Ther 18, 353\u2013360, doi: 10.1038\/mt.2009.195 (2010).","journal-title":"Mol Ther"},{"key":"BFsrep36182_CR23","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1182\/blood-2012-07-444877","volume":"121","author":"SF Whelan","year":"2013","unstructured":"Whelan, S. F. et al. Distinct characteristics of antibody responses against factor VIII in healthy individuals and in different cohorts of hemophilia A patients. Blood 121, 1039\u20131048, doi: 10.1182\/blood-2012-07-444877 (2013).","journal-title":"Blood"},{"key":"BFsrep36182_CR24","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/j.jaci.2013.01.014","volume":"131","author":"W van de Veen","year":"2013","unstructured":"van de Veen, W. et al. IgG4 production is confined to human IL-10-producing regulatory B cells that suppress antigen-specific immune responses. J Allergy Clin Immunol 131, 1204\u20131212, doi: 10.1016\/j.jaci.2013.01.014 (2013).","journal-title":"J Allergy Clin Immunol"},{"key":"BFsrep36182_CR25","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1111\/j.1398-9995.2008.01774.x","volume":"63","author":"F Meiler","year":"2008","unstructured":"Meiler, F., Klunker, S., Zimmermann, M., Akdis, C. A. & Akdis, M. Distinct regulation of IgE, IgG4 and IgA by T regulatory cells and toll-like receptors. Allergy 63, 1455\u20131463, doi: 10.1111\/j.1398-9995.2008.01774.x (2008).","journal-title":"Allergy"},{"key":"BFsrep36182_CR26","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1182\/blood-2010-12-326231","volume":"118","author":"E Martinuzzi","year":"2011","unstructured":"Martinuzzi, E. et al. acDCs enhance human antigen-specific T-cell responses. Blood 118, 2128\u20132137, doi: 10.1182\/blood-2010-12-326231 (2011).","journal-title":"Blood"},{"key":"BFsrep36182_CR27","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1160\/TH06-09-0519","volume":"97","author":"G Hu","year":"2007","unstructured":"Hu, G., Guo, D., Key, N. S. & Conti-Fine, B. M. Cytokine production by CD4+ T cells specific for coagulation factor VIII in healthy subjects and haemophilia A patients. Thromb Haemost 97, 788\u2013794 (2007).","journal-title":"Thromb Haemost"},{"key":"BFsrep36182_CR28","doi-asserted-by":"publisher","first-page":"6473","DOI":"10.4049\/jimmunol.176.11.6473","volume":"176","author":"B Knoechel","year":"2006","unstructured":"Knoechel, B. et al. Functional and molecular comparison of anergic and regulatory T lymphocytes. J Immunol 176, 6473\u20136483 (2006).","journal-title":"J Immunol"},{"key":"BFsrep36182_CR29","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1111\/cei.12445","volume":"178","author":"EM Moran","year":"2014","unstructured":"Moran, E. M. & Mastaglia, F. L. Cytokines in immune-mediated inflammatory myopathies: cellular sources, multiple actions and therapeutic implications. Clin Exp Immunol 178, 405\u2013415, doi: 10.1111\/cei.12445 (2014).","journal-title":"Clin Exp Immunol"},{"key":"BFsrep36182_CR30","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.ymgme.2012.05.004","volume":"106","author":"AT Palermo","year":"2012","unstructured":"Palermo, A. T. et al. Transcriptional response to GAA deficiency (Pompe disease) in infantile-onset patients. Mol Genet Metab 106, 287\u2013300, doi: 10.1016\/j.ymgme.2012.05.004 (2012).","journal-title":"Mol Genet Metab"},{"key":"BFsrep36182_CR31","doi-asserted-by":"crossref","unstructured":"Prendergast, C. T., Sanin, D. E. & Mountford, A. P. CD4 T cell hypo-responsiveness induced by schistosome larvae is not dependent upon eosinophils but may involve connective tissue mast cells. Parasite Immunol, doi: 10.1111\/pim.12300 (2015).","DOI":"10.1111\/pim.12300"},{"key":"BFsrep36182_CR32","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.immuni.2009.11.009","volume":"32","author":"PA Blair","year":"2010","unstructured":"Blair, P. A. et al. CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic Lupus Erythematosus patients. Immunity 32, 129\u2013140, doi: 10.1016\/j.immuni.2009.11.009 (2010).","journal-title":"Immunity"},{"key":"BFsrep36182_CR33","doi-asserted-by":"crossref","unstructured":"Kishnani, P. S. et al. Immune response to enzyme replacement therapies in lysosomal storage diseases and the role of immune tolerance induction. Mol Genet Metab, doi: 10.1016\/j.ymgme.2015.11.001 (2015).","DOI":"10.1016\/j.ymgme.2015.11.001"},{"key":"BFsrep36182_CR34","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1586\/1744666X.2014.926219","volume":"10","author":"M Keiserman","year":"2014","unstructured":"Keiserman, M. et al. The effect of antidrug antibodies on the sustainable efficacy of biologic therapies in rheumatoid arthritis: practical consequences. Expert Rev Clin Immunol 10, 1049\u20131057, doi: 10.1586\/1744666X.2014.926219 (2014).","journal-title":"Expert Rev Clin Immunol"},{"key":"BFsrep36182_CR35","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1055\/s-2000-9819","volume":"26","author":"SS Fakharzadeh","year":"2000","unstructured":"Fakharzadeh, S. S. & Kazazian, H. H., Jr. Correlation between factor VIII genotype and inhibitor development in hemophilia A. Semin Thromb Hemost 26, 167\u2013171, doi: 10.1055\/s-2000-9819 (2000).","journal-title":"Semin Thromb Hemost"},{"key":"BFsrep36182_CR36","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1038\/nbt1303","volume":"25","author":"G Shankar","year":"2007","unstructured":"Shankar, G., Pendley, C. & Stein, K. E. A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs. Nat Biotechnol 25, 555\u2013561, doi: 10.1038\/nbt1303 (2007).","journal-title":"Nat Biotechnol"},{"key":"BFsrep36182_CR37","doi-asserted-by":"publisher","first-page":"2541","DOI":"10.1002\/art.24709","volume":"60","author":"GM Bartelds","year":"2009","unstructured":"Bartelds, G. M. et al. Anti-adalimumab antibodies in rheumatoid arthritis patients are associated with interleukin-10 gene polymorphisms. Arthritis Rheum 60, 2541\u20132542, doi: 10.1002\/art.24709 (2009).","journal-title":"Arthritis Rheum"},{"key":"BFsrep36182_CR38","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1089\/hum.2013.092","volume":"24","author":"KM Flanigan","year":"2013","unstructured":"Flanigan, K. M. et al. Anti-dystrophin T cell responses in Duchenne muscular dystrophy: prevalence and a glucocorticoid treatment effect. Hum Gene Ther 24, 797\u2013806, doi: 10.1089\/hum.2013.092 (2013).","journal-title":"Hum Gene Ther"},{"key":"BFsrep36182_CR39","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1056\/NEJMoa1000228","volume":"363","author":"JR Mendell","year":"2010","unstructured":"Mendell, J. R. et al. Dystrophin immunity in Duchenne\u2019s muscular dystrophy. N Engl J Med 363, 1429\u20131437, doi: 10.1056\/NEJMoa1000228 (2010).","journal-title":"N Engl J Med"},{"key":"BFsrep36182_CR40","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1097\/01.gim.0000218152.87434.f3","volume":"8","author":"AWGoMoP Disease","year":"2006","unstructured":"Disease, A. W. G. o. M. o. P. et al. Pompe disease diagnosis and management guideline. Genet Med 8, 267\u2013288, doi: 10.109701.gim.0000218152.87434.f3 (2006).","journal-title":"Genet Med"},{"key":"BFsrep36182_CR41","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.ymgme.2012.04.027","volume":"106","author":"TT Patel","year":"2012","unstructured":"Patel, T. T. et al. The impact of antibodies in late-onset Pompe disease: a case series and literature review. Mol Genet Metab 106, 301\u2013309, doi: 10.1016\/j.ymgme.2012.04.027 (2012).","journal-title":"Mol Genet Metab"},{"key":"BFsrep36182_CR42","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/jth.12065","volume":"11","author":"A Wroblewska","year":"2013","unstructured":"Wroblewska, A., Reipert, B. M., Pratt, K. P. & Voorberg, J. Dangerous liaisons: how the immune system deals with factor VIII. J Thromb Haemost 11, 47\u201355, doi: 10.1111\/jth.12065 (2013).","journal-title":"J Thromb Haemost"},{"key":"BFsrep36182_CR43","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1111\/nan.12214","volume":"41","author":"AC Nascimbeni","year":"2015","unstructured":"Nascimbeni, A. C., Fanin, M., Tasca, E., Angelini, C. & Sandri, M. Impaired autophagy affects acid alpha-glucosidase processing and enzyme replacement therapy efficacy in late-onset glycogen storage disease type II. Neuropathol Appl Neurobiol 41, 672\u2013675, doi: 10.1111\/nan.12214 (2015).","journal-title":"Neuropathol Appl Neurobiol"},{"key":"BFsrep36182_CR44","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.neulet.2007.11.028","volume":"431","author":"A Lucia","year":"2008","unstructured":"Lucia, A. et al. McArdle disease: another systemic low-inflammation disorder? Neurosci Lett 431, 106\u2013111, doi: 10.1016\/j.neulet.2007.11.028 (2008).","journal-title":"Neurosci Lett"},{"key":"BFsrep36182_CR45","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1093\/qjmed\/90.1.19","volume":"90","author":"MJ Allen","year":"1997","unstructured":"Allen, M. J., Myer, B. J., Khokher, A. M., Rushton, N. & Cox, T. M. Pro-inflammatory cytokines and the pathogenesis of Gaucher\u2019s disease: increased release of interleukin-6 and interleukin-10. QJM 90, 19\u201325 (1997).","journal-title":"QJM"},{"key":"BFsrep36182_CR46","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/gim.2011.4","volume":"14","author":"YH Messinger","year":"2012","unstructured":"Messinger, Y. H. et al. Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease. Genet Med 14, 135\u2013142, doi: 10.1038\/gim.2011.4 (2012).","journal-title":"Genet Med"},{"key":"BFsrep36182_CR47","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/gim.2012.110","volume":"15","author":"SG Banugaria","year":"2013","unstructured":"Banugaria, S. G. et al. Bortezomib in the rapid reduction of high sustained antibody titers in disorders treated with therapeutic protein: lessons learned from Pompe disease. Genet Med 15, 123\u2013131, doi: 10.1038\/gim.2012.110 (2013).","journal-title":"Genet Med"},{"key":"BFsrep36182_CR48","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1111\/hae.12646","volume":"21","author":"SA Montalvao","year":"2015","unstructured":"Montalvao, S. A. et al. A longitudinal evaluation of anti-FVIII antibodies demonstrated IgG4 subclass is mainly correlated with high-titre inhibitor in haemophilia A patients. Haemophilia 21, 686\u2013692, doi: 10.1111\/hae.12646 (2015).","journal-title":"Haemophilia"},{"key":"BFsrep36182_CR49","doi-asserted-by":"publisher","first-page":"e220","DOI":"10.1097\/MPH.0000000000000287","volume":"37","author":"PC Moorehead","year":"2015","unstructured":"Moorehead, P. C. et al. Rapid acquisition of immunologic tolerance to factor VIII and disappearance of anti-factor VIII IgG4 after prophylactic therapy in a hemophilia A patient with high-titer factor VIII inhibitor. J Pediatr Hematol Oncol 37, e220\u2013e222, doi: 10.1097\/MPH.0000000000000287 (2015).","journal-title":"J Pediatr Hematol Oncol"},{"key":"BFsrep36182_CR50","doi-asserted-by":"publisher","first-page":"4678","DOI":"10.1172\/JCI78891","volume":"124","author":"CA Akdis","year":"2014","unstructured":"Akdis, C. A. & Akdis, M. Mechanisms of immune tolerance to allergens: role of IL-10 and Tregs. J Clin Invest 124, 4678\u20134680, doi: 10.1172\/JCI78891 (2014).","journal-title":"J Clin Invest"},{"key":"BFsrep36182_CR51","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1016\/j.jaci.2015.07.031","volume":"136","author":"A Renand","year":"2015","unstructured":"Renand, A. et al. Chronic cat allergen exposure induces a TH2 cell-dependent IgG4 response related to low sensitization. J Allergy Clin Immunol 136, 1627\u20131635, e1613, doi: 10.1016\/j.jaci.2015.07.031 (2015).","journal-title":"J Allergy Clin Immunol"},{"key":"BFsrep36182_CR52","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1016\/j.jaci.2015.01.012","volume":"135","author":"AF Santos","year":"2015","unstructured":"Santos, A. F. et al. IgG4 inhibits peanut-induced basophil and mast cell activation in peanut-tolerant children sensitized to peanut major allergens. J Allergy Clin Immunol 135, 1249\u20131256, doi: 10.1016\/j.jaci.2015.01.012 (2015).","journal-title":"J Allergy Clin Immunol"},{"key":"BFsrep36182_CR53","doi-asserted-by":"crossref","first-page":"722","DOI":"10.4049\/jimmunol.130.2.722","volume":"130","author":"RC Aalberse","year":"1983","unstructured":"Aalberse, R. C., van der Gaag, R. & van Leeuwen, J. Serologic aspects of IgG4 antibodies. I. Prolonged immunization results in an IgG4-restricted response. J Immunol 130, 722\u2013726 (1983).","journal-title":"J Immunol"},{"key":"BFsrep36182_CR54","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1046\/j.1365-2141.1996.d01-1705.x","volume":"93","author":"F Dazzi","year":"1996","unstructured":"Dazzi, F. et al. High incidence of anti-FVIII antibodies against non-coagulant epitopes in haemophilia A patients: a possible role for the half-life of transfused FVIII. Br J Haematol 93, 688\u2013693 (1996).","journal-title":"Br J Haematol"},{"key":"BFsrep36182_CR55","doi-asserted-by":"publisher","first-page":"2868","DOI":"10.1172\/JCI34676","volume":"118","author":"P Dickson","year":"2008","unstructured":"Dickson, P. et al. Immune tolerance improves the efficacy of enzyme replacement therapy in canine mucopolysaccharidosis I. J Clin Invest 118, 2868\u20132876, doi: 10.1172\/JCI34676 (2008).","journal-title":"J Clin Invest"},{"key":"BFsrep36182_CR56","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1016\/S0140-6736(03)13311-9","volume":"361","author":"R Kakavanos","year":"2003","unstructured":"Kakavanos, R., Turner, C. T., Hopwood, J. J., Kakkis, E. D. & Brooks, D. A. Immune tolerance after long-term enzyme-replacement therapy among patients who have mucopolysaccharidosis I. Lancet 361, 1608\u20131613, doi: 10.1016\/S0140-6736(03)13311-9 (2003).","journal-title":"Lancet"},{"key":"BFsrep36182_CR57","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1089\/hum.2014.115","volume":"26","author":"SO Han","year":"2015","unstructured":"Han, S. O. et al. Enhanced efficacy from gene therapy in Pompe disease using coreceptor blockade. Hum Gene Ther 26, 26\u201335, doi: 10.1089\/hum.2014.115 (2015).","journal-title":"Hum Gene Ther"},{"key":"BFsrep36182_CR58","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1159\/000056717","volume":"77","author":"J Oldenburg","year":"1999","unstructured":"Oldenburg, J., Schwaab, R. & Brackmann, H. H. Induction of immune tolerance in haemophilia A inhibitor patients by the \u2018Bonn Protocol\u2019: predictive parameter for therapy duration and outcome. Vox Sang 77 Suppl 1, 49\u201354, doi: 56717 (1999).","journal-title":"Vox Sang"},{"key":"BFsrep36182_CR59","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1084\/jem.20030913","volume":"198","author":"NJ Singh","year":"2003","unstructured":"Singh, N. J. & Schwartz, R. H. The strength of persistent antigenic stimulation modulates adaptive tolerance in peripheral CD4+ T cells. J Exp Med 198, 1107\u20131117, doi: 10.1084\/jem.20030913 (2003).","journal-title":"J Exp Med"},{"key":"BFsrep36182_CR60","doi-asserted-by":"crossref","unstructured":"Kazi, Z. B. et al. Durable and sustained immune tolerance to ERT in Pompe disease with entrenched immune responses. JCI Insight 1, doi: 10.1172\/jci.insight.86821 (2016).","DOI":"10.1172\/jci.insight.86821"},{"key":"BFsrep36182_CR61","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.ymgme.2009.07.001","volume":"98","author":"SE Lipinski","year":"2009","unstructured":"Lipinski, S. E., Lipinski, M. J., Burnette, A., Platts-Mills, T. A. & Wilson, W. G. Desensitization of an adult patient with Pompe disease and a history of anaphylaxis to alglucosidase alfa. Mol Genet Metab 98, 319\u2013321, doi: 10.1016\/j.ymgme.2009.07.001 (2009).","journal-title":"Mol Genet Metab"},{"key":"BFsrep36182_CR62","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s10072-014-2000-5","volume":"36","author":"JS Park","year":"2015","unstructured":"Park, J. S., Kim, H. G., Shin, J. H., Choi, Y. C. & Kim, D. S. Effect of enzyme replacement therapy in late onset Pompe disease: open pilot study of 48 weeks follow-up. Neurol Sci 36, 599\u2013605, doi: 10.1007\/s10072-014-2000-5 (2015).","journal-title":"Neurol Sci"},{"key":"BFsrep36182_CR63","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/0009-8981(73)90234-9","volume":"49","author":"H Galjaard","year":"1973","unstructured":"Galjaard, H., Mekes, M., Josselin de Jong, J. D. & Niermeijer, M. F. A method for rapid prenatal diagnosis of glycogenosis II (Pompe\u2019s disease). Clin Chim Acta 49, 361\u2013375 (1973).","journal-title":"Clin Chim Acta"},{"key":"BFsrep36182_CR64","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1182\/blood-2008-07-167510","volume":"114","author":"F Mingozzi","year":"2009","unstructured":"Mingozzi, F. et al. AAV-1-mediated gene transfer to skeletal muscle in humans results in dose-dependent activation of capsid-specific T cells. Blood 114, 2077\u20132086, doi: 10.1182\/blood-2008-07-167510 (2009).","journal-title":"Blood"},{"key":"BFsrep36182_CR65","doi-asserted-by":"crossref","unstructured":"Verbeke, G. & Molenberghs, G. Linear Mixed Models for Longitudinal Data. Springer, New York, NY, USA (2000).","DOI":"10.1007\/978-1-4419-0300-6"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep36182.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep36182","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep36182.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T01:41:10Z","timestamp":1672882870000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep36182"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,4]]},"references-count":65,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,12,21]]}},"alternative-id":["BFsrep36182"],"URL":"https:\/\/doi.org\/10.1038\/srep36182","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,4]]},"assertion":[{"value":"27 April 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Pascal Laforet has received grants and honoraria from Genzyme Company, and honoraria from BioMarin and Amicus Therapeutics and all the other authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"36182"}}